Axim Biotechnologies Files Pre-Submission With FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic Test
Axim's TearScan Lf is the first and only FDA 510 (k)-cleared point-of-care (POC) diagnostic test specifically intended to support the diagnosis of Aqueous Deficient Dry Eye Disease (ADDE). Lactoferrin tear levels are a convenient POC diagnostic that aids in determining the viability of the lacrimal gland. Lactoferrin levels are reduced in 80% of patients with ADDE. By distinguishing ADDE from other forms of Dry Eye Disease, the test helps avoid trial-and-error use of therapies that are ineffective for tear deficiency. Additionally, because Lactoferrin levels reflect lacrimal gland function, repeated testing allows the physician to monitor response to treatment and disease progression over time.
The Pre-Sub Q process allows device developers to engage early with the FDA to receive feedback, clarify regulatory expectations, and minimize risks of delays during the formal waiver application. FDA feedback is anticipated within 60 days. Upon FDA feedback, the company plans to conduct a comparative clinical study to support its CLIA Waiver Application, which is expected to be submitted later this year. The FDA typically completes review of CLIA Waiver Applications within 90 days.
Currently, facilities must obtain CLIA certification and adhere to laboratory protocols in order to administer Axim's Lactoferrin test. A CLIA waiver would eliminate the certification requirement and enable administration of the point-of-care Lactoferrin test by ophthalmologists and optometrists in non-laboratory settings thereby allowing for far broader clinical use and accelerating commercial adoption.
'The Company's Pre-Sub Q submission marks a significant milestone in its strategy to broaden access to its tests by obtaining a CLIA waiver. We are committed to making it easier for eye care providers to integrate our tests into their practices without complex lab infrastructure,' said Catalina Valencia, CEO of Axim Biotechnologies. 'Today's submission is the first step in that process, and we believe it will open the door to widespread use of our Lactoferrin test - and soon after, our IgE test - in primary eye care and beyond. We believe that securing CLIA waivers for our Lactoferrin and IgE tests will be transformative, unlocking significant commercial opportunities in the U.S. market and enabling earlier, more accessible diagnosis of Dry Eye Disease, including ADDE and ocular allergy. As a CLIA waived, semi‑quantitative, point-of-care biomarker test, TearScan Lf would be well-positioned to capture market share in the diagnostic device segment for Dry Eye.'
About AXIM(R) Biotechnologies
Founded in 2014, AXIM(R) Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dry Eye Disease. For more information, please visit www.AXIMBiotech.com.
Corporate/Media Contact Info:
+1 858-256-5132
[email protected]
Forward-Looking Statements
The statements made by Axim Biotechnologies Inc., in this press release may be 'forward-looking' in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will ever be approved for use by the U.S. FDA or any equivalent foreign regulatory agency. Further, Axim's eye care diagnostic products that are FDA cleared may not be manufactured in large enough quantities or that third parties with established eye care physicians will enter into agreements or purchase from the Company, and even if the Company's diagnostic candidates are successful, they may generate only limited revenue and profits for the Company. Various other factors are detailed from time to time in Axim's Reports filed on OTCMarkets.com
Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Novo Nordisk, WeightWatchers expand collaboration
WW International (WGHTH) 'announced an expanded collaboration with Novo Nordisk (NVO), which includes increased access to authentic, FDA-approved Wegovy injection through WeightWatchers (WGHTQ) Clinic. As the only holistic platform focused on long-term weight health featuring the No. 1 doctor-recommended weight loss program included in the recently announced collaboration with Novo Nordisk, WeightWatchers continues to reinforce its role as the trusted leader in sustainable, science-backed weight care, and one of the few in the industry to publicly commit to prescribing only FDA-approved medications. As part of the collaboration, WeightWatchers Clinic members will benefit from a simplified prescription process via NovoCare Pharmacy. CenterWell Pharmacy, a seven-time MMIT Specialty Pharmacy Patient Choice Award winner for best-in-class customer satisfaction and commitment to patient care, serves as the dispensing pharmacy for the NovoCare program and will facilitate direct fulfillment and home delivery of Wegovy prescriptions for WeightWatchers Clinic members. In addition, WeightWatchers will enhance the member experience by providing integrated account access, bundled pricing opportunities, inventory visibility, and shipment tracking. Additionally, Novo Nordisk is offering a limited-time savings offer available to WeightWatchers Clinic members. Starting July 1, 2025, eligible cash-pay members can access Wegovy at a reduced price of $299 until July 31, 2025-a significant savings aimed at expanding access to clinically validated, FDA-regulated treatment options.'
Time Business News
5 hours ago
- Time Business News
Plasma Pen: The Non-Surgical Revolution in Skin Rejuvenation
In the world of advanced skincare and aesthetic treatments, the Plasma Pen is making waves as a revolutionary non-invasive solution for skin tightening, lifting, and rejuvenation. With its ability to stimulate collagen production and improve skin texture without surgery, become a go-to treatment for those seeking youthful, smoother skin without the risks and downtime of traditional procedures. In this in-depth blog, we'll explore everything you need to know about what it is, how it works, who it's for, benefits, potential side effects, and what to expect during and after treatment. A Plasma Pen is an FDA-approved device used in aesthetic medicine to perform fibroblast therapy, a skin-tightening and lifting treatment. The device uses plasma energy, created by ionizing the gas in the air between its tip and the skin surface, forming a small electrical arc. This arc creates controlled micro-trauma on the skin's surface, triggering the body's natural healing process. The result? Increased collagen and elastin production, which leads to tighter, firmer, and more youthful-looking skin over time. The Plasma converts electrical energy into an electrostatic charge that is transmitted through a disposable probe. When the is brought close to the skin, it ionizes the oxygen and nitrogen in the air, creating a small plasma flash. This arc never touches the skin but creates tiny micro-injuries on the epidermis (outer layer), stimulating the fibroblasts in the dermis to produce new collagen and regenerate tissue. This process: Tightens loose skin Reduces wrinkles and fine lines Improves skin texture and tone Promotes natural healing The Plasma Pen is versatile and can address a wide range of skin concerns, including: Fine lines and wrinkles Crows' feet Droopy eyelids (non-surgical blepharoplasty) Forehead lines Smile lines Neck lines (turkey neck) Stretch marks Scars and acne scars Age spots and pigmentation The device is most commonly used on the face and neck, but it can also be used on the abdomen, knees, and other parts of the body. Benefits of Plasma Pen Treatment No incisions, no stitches, and no general anesthesia required. It's a perfect option for people seeking an alternative to surgical lifts and tucks. While there's some temporary redness and scabbing, the recovery is relatively short, typically 7–10 days compared to weeks for surgery. The results develop gradually over several weeks as collagen rebuilds, giving a more natural and subtle enhancement. With proper skin care, results can last 2–3 years or more. Maintenance treatments may be performed as needed. Trained practitioners can precisely target problem areas without affecting surrounding tissues. Ideal candidates for Plasma Pen treatment are individuals who: Are in good general health Have mild to moderate skin laxity Are non-smokers Have realistic expectations Are not pregnant or breastfeeding People with darker skin tones may need to consult with their provider about the risks of hyperpigmentation or hypopigmentation, as plasma treatments can occasionally affect melanin. Your provider will assess your skin, discuss your goals, and determine if the Plasma Pen is the right treatment for you. Topical numbing cream is applied to ensure comfort during the procedure. This is typically left on for 30–60 minutes. The Plasma Pen is moved across targeted areas, creating a series of tiny dots (carbon crusts) where the plasma energy comes into contact with the skin. The session typically lasts 30 to 90 minutes, depending on the treatment area. You'll receive detailed aftercare instructions. Swelling and redness are common for the first few days, followed by the formation of small scabs. These crusts naturally fall off within a week. Do not pick at the scabs. Allow them to fall off naturally to avoid scarring. Allow them to fall off naturally to avoid scarring. Avoid direct sun exposure for at least 2 weeks. Use SPF 50+ daily. for at least 2 weeks. Use SPF 50+ daily. Skip makeup until your provider gives you the all-clear. until your provider gives you the all-clear. Use only recommended products to soothe and hydrate the skin (usually a healing balm or cream). to soothe and hydrate the skin (usually a healing balm or cream). Avoid hot showers, saunas, and excessive sweating during the first 7–10 days. Initial tightening may be noticeable within a week, but full results typically develop over 8 to 12 weeks as collagen regenerates. Many patients require only one session, while others may benefit from two or more treatments spaced several weeks apart. When performed by a certified and trained professional, it is considered safe. However, like any aesthetic procedure, there are potential risks: Swelling and redness Scabbing or crusting Hyperpigmentation or hypopigmentation Infection (rare) Prolonged healing occurs if aftercare is not followed Always choose a reputable provider with experience using the Plasma Pen device. Treatment Invasiveness Downtime Results Duration Cost Plasma Pen Non-surgical 7–10 days 2–3 years Moderate Botox Non-surgical Minimal 3–6 months Low to moderate Microneedling Non-surgical 1–3 days 6–12 months Low Surgical Facelift Invasive 3–4 weeks 5–10 years High The Plasma Pen bridges the gap between injectables and surgical procedures, offering a cost-effective alternative with long-lasting results. Conclusion: Is the Plasma Pen Right for You? If you're looking for a powerful, non-invasive way to rejuvenate your skin, tighten problem areas, and reduce signs of aging, the Plasma Pen could be the ideal solution. With its ability to stimulate collagen naturally, this treatment provides long-term benefits without the risk and downtime of traditional surgery. Whether you're considering treatment for fine lines around the eyes, loose skin on the neck, or acne scars, always consult a licensed aesthetic provider for a personalized recommendation. Further, for more, you can donate freedom plasma Ready to reveal younger, firmer skin? The Plasma Pen might be your secret weapon. TIME BUSINESS NEWS
CBS News
6 hours ago
- CBS News
Family of Penn Hills officer who died by suicide after Lasik surgery receives letter from FDA
A young Pittsburgh-area police officer died by suicide and pointed to Lasik eye surgery complications as the reason. Now his Penn Hills family is demanding industry accountability. Ryan Kingerski's family members said the 26-year-old's Lasik eye surgery led to unbearable pain. They say if doctors and industry leaders highlighted or even conveyed the real, much higher complication numbers, patients would be better educated about the risks. They believe the industry is trying to downplay complications and silence people like their late son. FDA sends letter to Ryan Kingerski's family In an interview with KDKA-TV earlier this year, mom Stefanie Kingerski described her son Ryan as "witty, charming, smart." But the dedicated Penn Hills police officer died by suicide after struggling with debilitating side effects following Lasik, which is an elective eye surgery. "He kept saying about how bad the pain in his head was. He had a terrible headache and wasn't able to focus, and the vision and the blurriness and everything else," dad Tim Kingerski previously explained. Now Tim and Stefanie Kingerski are fighting for industry accountability, sharing with KDKA Investigates a new response letter they say they received from the Food and Drug Administration, signed by the FDA's consumer team. They say it proves acknowledgement of what they call a gross underreporting of adverse side effects. It says the FDA inspector "has been following these Laser Lasik incidences for several years. He explained there is under-reporting by the Ophthalmic Clinics because they are not submitting the required patient injuries to the FDA." The letter also says the FDA is "actively looking into sending out a 'warning notice' to the public about the risks" of Lasik. FDA adviser who approved Lasik says he regrets it "I tell people that ask me, and even if they don't ask, it's 'trust but verify.' If they say it's 1%, go look it up, go find out what is the actual rate," said retired FDA adviser Dr. Morris Waxler. Waxler voted to approve Lasik three decades ago, but now he says he regrets it and is one of Lasik's biggest critics after his independent review of the data. "They'll make a long list if they provide any information about informed consent. Provide a long list of things that could happen, but they will not provide actual percentages because they know the percentages are really high. They're 10% to 20% to 30%, some as high as 75%, depending on what you're measuring." The FDA warns on its website that some patients may lose vision and develop debilitating visual symptoms, adding that the long-term safety and effectiveness of Lasik surgery is not known. Still, supporters of Lasik tout a 1% complication rate. "And all I can do is provide the information, and they can look it up. And you can ask the surgeon, 'Well, why don't you cite that study? Why are you ignoring that study? Why are you not pointing this out? Is there something wrong with those studies? Why have you ignored this whole body of literature?' So you need to ask them questions," Waxler said. Red flags for any elective procedure include you feel like you're receiving a sales pitch, a surgeon promises perfection, there's pressure to make a decision quickly, side effects are not highlighted or minimized and it feels more like a business transaction than medical care. Waxler points out Lasik is very attractive to young people, public servants, like police officers like Ryan, and military members. U.S. congressman talking with FDA The Kingerski family said Congressman Chris Deluzio is now looking into this, given his military background, and hoping to find answers, as well. "Congressman Deluzio's office is engaging with the FDA to see what can be done to avoid terrible tragedies like Officer Kingerski's from happening in the future. Our brave cops have hard enough jobs; nobody should worry about losing their life after something like this," his spokesperson said in a statement. KDKA-TV also reached out directly to the FDA and was told, "The FDA does not discuss possible or ongoing investigations."
